BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31485626)

  • 1. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism.
    Li B; Zhang J; Su Y; Hou Y; Wang Z; Zhao L; Sun S; Fu H
    Mol Med Rep; 2019 Oct; 20(4):3793-3801. PubMed ID: 31485626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
    Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
    Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
    Liu J; Xing Y; Rong L
    Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L; Zhang J; Fan Y; Li Y
    Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pectolinarigenin inhibits non‑small cell lung cancer progression by regulating the PTEN/PI3K/AKT signaling pathway.
    Xu F; Gao X; Pan H
    Oncol Rep; 2018 Dec; 40(6):3458-3468. PubMed ID: 30542737
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
    Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
    [No Abstract]   [Full Text] [Related]  

  • 9. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
    Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
    Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
    Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
    Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein.
    Bu T; Wang C; Jin H; Meng Q; Huo X; Sun H; Sun P; Wu J; Ma X; Liu Z; Liu K
    J Cell Physiol; 2020 Apr; 235(4):3309-3319. PubMed ID: 31587272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy.
    Sai X; Qin C; Wu Y; Zhao Y; Bian T
    J Int Med Res; 2020 May; 48(5):300060520923522. PubMed ID: 32436415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
    Wang F; Mao Y; You Q; Hua D; Cai D
    Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
    Feng FF; Cheng P; Sun C; Wang H; Wang W
    Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on
    Mohiuddin M; Kasahara K
    Cancer Genomics Proteomics; 2021; 18(4):579-590. PubMed ID: 34183390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.